![](http://www.dndi.org/newsletters/n10/img/titre-part.gif) DNDi-Sanofi Aventis sign agreement on AS/AQ DNDi has developed a fixed-dose formulation of artesunate amodiaquine (AS/AQ) for the treatment of malaria. This combination has the two drugs, artesunate and amodiaquine, in one tablet... ![](http://www.dndi.org/newsletters/n10/img/titre-fund.gif) Canton of Geneva commits 200,000CHF to DNDi East Africa Project The Canton of Geneva has committed an initial 200,000 CHF to the DNDi-LEAP Paromomycin Clinical Trial in Sudan, Ethiopia and Kenya for visceral leishmaniasis. The objective of this project is to make a more effective, shorter course, less toxic treatment... ![](http://www.dndi.org/newsletters/n10/img/traitgris.gif) DNDi's Scientific Advisory Committee DNDis Scientific Advisory Committee is a group of 15 scientists from different backgrounds and countries...
| | ![](http://www.dndi.org/newsletters/n10/img/titre-port.gif) Drug development pipeline In keeping with its R&D strategy, DNDi hopes to build a mixed balanced pipeline of short, medium and long term projects... ![](http://www.dndi.org/newsletters/n10/img/pipeline.gif)
![](http://www.dndi.org/newsletters/n10/img/traitgris.gif) Meet Nubia Boechat, MSc, PhD Dr Nubia Boechat is a member of DNDis Scientific Advisory Committee...
|